TCON News and Press, TRACON Pharmaceuticals Inc. From 11/20/23

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with oth...

2023-11-13 09:57:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Joby Aviation (NYSE: JOBY ) stock is a hot topic among traders on Monday after the company secured a new tax credit to build a new factory in Ohio. This new facility would o...

2023-11-13 09:29:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company’s shares retreat from a massive rally on Friday. That rally saw shares of TCON stock clim...

2023-11-09 21:10:07 ET TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Results Conference Call November 09, 2023 04:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright ...

2023-11-09 16:03:37 ET More on Tracon Seeking Alpha’s Quant Rating on Tracon Historical earnings data for Tracon Financial information for Tracon For further details see: Tracon GAAP EPS of $0.29

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other lif...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

TRACON Pharmaceuticals Inc. (TCON) is expected to report for Q3 2023

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other lif...

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life sci...